Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
深圳市海王生物工程股份有限公司营业收入扣除情况表专项核查报告
Regulatory Filings
2023-04-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, participants, and the resolutions passed, including approval of the 2022 Supervisory Board Work Report, 2022 Financial Statements, 2022 Profit Distribution Plan, 2022 Annual Report, 2023 Q1 Report, internal control self-assessment, remuneration proposals, audit firm renewal, related party transactions, and guarantees for subsidiaries. The document repeatedly references that the detailed reports are published elsewhere (on cninfo.com.cn and various newspapers) and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full reports or substantive financial data but is an official announcement of the Supervisory Board's meeting resolutions and approvals. It is not the report itself but an announcement of the meeting decisions and approvals. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the full Annual Report or Interim Report.
2023-04-27 Chinese
监事会关于第九届监事会第四次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review opinions on various company reports and proposals, including the 2022 annual report, 2023 first quarter report, profit distribution plan, internal control self-evaluation report, and other governance matters. It contains no actual financial statements or detailed financial data but rather opinions and confirmations on the reports and proposals prepared by the board. The document length is short (1356 characters), and it serves as an audit or supervisory opinion rather than the full annual or quarterly report itself. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports or interim reports. FY 2022
2023-04-27 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2023年第一次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of the convening and conduct of Shenzhen Haiwang Bioengineering Co., Ltd.'s 2023 first extraordinary general meeting of shareholders. It details the meeting's notice, attendance, voting procedures, and results, and confirms that the meeting and its resolutions comply with relevant laws and company regulations. The document does not contain financial statements or management discussion but is a legal certification related to a shareholders meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and validates the meeting's legality.
2023-04-20 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as the "2023 First Extraordinary General Meeting Resolution Announcement" of Shenzhen Haiwang Bioengineering Co., Ltd. It details the date, voting methods, attendance, and voting results of the meeting. It includes resolutions passed and legal opinions confirming the validity of the meeting and resolutions. The document is an official announcement of the voting results from a shareholders' meeting, not the meeting materials or the full report itself. The document length is 2656 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-04-20 Chinese
关于召开2023年第一次临时股东大会通知的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement about the convening of the 2023 first extraordinary general meeting of shareholders for Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration methods, and proxy authorization forms. There is no financial data or report content, but rather a notice and instructions related to a shareholders' meeting. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Proxy Solicitation & Information Statement (PSI). However, since it is primarily a notice about the meeting and voting procedures rather than solicitation materials, it aligns best with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and is an announcement, not a report itself, so it is not an Annual Report or Interim Report. Therefore, the correct classification is DVA with high confidence.
2023-04-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.